Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Select a campus/region

The Aortix CRS Pilot Study

  • Status
    Accepting Candidates
  • Age
    21 Years - N/A
  • Sexes
  • Healthy Volunteers


The Aortix Crs Pilot Study: An Evaluation of the Safety and Performance of the Aortix System for Intra-Aortic Mechanical Circulatory Support in Patients with Cardiorenal Syndrome


The study is a prospective, multi-center, non-randomized feasibility study to evaluate the safety and performance of the Aortix System in patients hospitalized with acute decompensated heart failure (ADHF) and worsening renal function refractory to medical management with persistent congestion. The Aortix system consists of the Aortix Delivery System, Introducer Set, the Aortix Pump, the Aortix Control System, and the Aortix Retrieval System.


Full study title An Evaluation of the Safety and Performance of the Aortix System for Intra-Aortic Mechanical Circulatory Support in Patients With Cardiorenal Syndrome
Protocol number OCR37322 ID NCT04145635
Phase N/A


Inclusion Criteria:

  1. Admitted to the hospital with a primary diagnosis of acute decompensated heart failure, either heart failure with reduced or preserved ejection fraction (HFrEF, HFpEF or HFmEF);

  2. Worsening renal function (serum creatinine increase by ≥0. 3 mg/dl [≥27 μmol/L]) despite 48 hours of intravenous diuretic therapy Increase can be compared to a baseline value taken within 90 days of hospitalization or during hospitalization;

  3. Objective measure of congestion (Elevated PCWP [≥20 mmHg] OR Elevated CVP [≥12 mmHg]) obtained via catheter measurement;

  4. Persistent clinical signs and/or symptoms of congestion despite diuretic therapy (one or more of the following):

  1. dyspnea at rest or with minimal exertion,

  2. paroxysmal nocturnal dyspnea,

  3. orthopnea,

  4. lower extremity edema (≥2+),

  5. elevated jugular venous pressure,

  6. pulmonary rales,

  7. enlarged liver or ascites,

  8. pulmonary vascular congestion on chest x-ray;

    1. Age >21 years. -

Exclusion Criteria:

  1. Treatment with high dose IV inotropes within the last 48 hours. High dose is defined as > 1 unit of inotrope (excluding digoxin) as follows: 5 µg/kg/min dopamine = 1 unit, 5 µg/kg/min dobutamine= 1 unit, 0.375 µg/kg/min milrinone = 1 unit, (for example, dopamine 2.5 µg/kg/min + dobutamine 2.5 µg/kg/min = 1 unit; dobutamine 2.5 µg/kg/min + milrinone 0.1875 µg/kg/min = 1 unit);

  2. Treatment with vasopressors to maintain blood pressure as per exclusion number 3;

  3. Active and ongoing hypotension defined as a systolic blood pressure < 90 mmHg lasting more than 30 minutes or a mean arterial pressure (MAP) < 60 mmHg lasting more than 30 minutes;

  4. Acute Kidney Failure defined as increase in serum creatinine to ≥4. 0 mg/dL (≥353. 6 μmol/L) within the last 48 hours;

  5. Exposure to intravenous contrast, aminoglycosides or high dose NSAIDS in the 48 hours before enrollment;

  6. Known or suspected contrast induced nephropathy;

  7. Prior kidney transplant, isolated single kidney, stage V Chronic Kidney Disease (eGFR ≤15) at admission OR use of dialysis, continuous renal replacement therapy (CRRT) or aquapheresis (ultrafiltration) in last 90 days;

  8. Urologic intervention (except indwelling urinary (Foley) catheter)) within the last 7 days;

  9. Known cirrhosis or shock liver;

  10. Presence of an active infection;

  11. Prior heart transplant in the last 2 years, heart failure due to rejection of a previous heart transplant, planned heart transplantation before the 30-day follow-up visit;

  12. Current or previous support with a durable LVAD at any time or use of an intra-aortic balloon pump, extracorporeal membrane oxygenation (ECMO), or percutaneous ventricular assist devices (e.g. Impella or TandemHeart) currently or within the last 30 days;

  13. Patient has known hypo* or hyper coaguable state such as disseminated intravascular coagulation or heparin induced thrombocytopenia (HIT);

  14. Known cardiac amyloidosis;

  15. Acute myocardial infarction Type 1 within 30 days of enrollment, or planned coronary revascularization;

  16. Stroke within 30 days of enrollment;

  17. Severe Bleeding Risk (any of the following):

a) Previous intracranial bleed unless there is documentation in the medical record (from a

physician that is not part of the study) that the patient can safely use anticoagulation

for 7 days, b) GI bleeding within 6 months requiring hospitalization and/or transfusion, c)

Recent major surgery within 6 months if the surgical wound is judged to be associated with

an increased risk of bleeding, d) Endovascular procedure with ilio-femoral access > 6 FR

within 30 days, e) Platelet count

Lead researcher

  • Advanced Heart Failure and Transplant Specialist, Cardiologist (Heart Specialist)
    Mustafa M Ahmed

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step


    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.